Stamatovic Svetlana M, Shakui Parvin, Keep Richard F, Moore Bethany B, Kunkel Steven L, Van Rooijen Nico, Andjelkovic Anuska V
Department of Neurosurgery, Pulmonary and Critical Care Medicine, Ann Arbor, MI 48109-0532, USA.
J Cereb Blood Flow Metab. 2005 May;25(5):593-606. doi: 10.1038/sj.jcbfm.9600055.
The present study was designed to elucidate the effects of the chemokine monocyte chemoattractant protein (MCP-1) on blood-brain barrier (BBB) permeability. Experiments were conducted under in vitro conditions (coculture of brain endothelial cells and astrocytes) to study the cellular effects of MCP-1 and under in vivo conditions (intracerebral and intracerebroventricular administration of MCP-1) to study the potential contribution of MCP-1 to BBB disruption in vivo. Our results showed that MCP-1 induces a significant increase in the BBB permeability surface area product for fluorescein isothiocyanate (FITC)-albumin under in vivo conditions, particularly during prolonged (3 or 7 days) exposure (0.096+/-0.008 versus 0.031+/-0.005 microL/g min in controls at 3 days, P<0.001). Monocyte chemoattractant protein-1 also enhanced (17-fold compared with control) the permeability of the in vitro BBB (coculture) model. At the cellular level, MCP-1 causes alteration of tight junction (TJ) proteins in endothelial cells (redistribution of TJ proteins determined by Western blotting and loss of immunostaining for occludin, claudin-5, ZO-1, ZO-2). Monocyte chemoattractant protein-1-induced alterations in BBB permeability are mostly realized through the CCR2 receptor. Absence of CCR2 diminishes any effect of MCP-1 on BBB permeability in vitro and in vivo. The permeability surface area product for FITC-albumin after 3 days exposure to MCP-1 was 0.096+/-0.006 and 0.032+/-0.007 microL/g min, in CCR2+/+ and CCR2-/- mice, respectively (P<0.001). Monocytes/macrophages also participate in MCP-1-induced alterations in BBB permeability in vivo. Monocytes/macrophages depletion (by clodronate liposomes) reduced the effect of MCP-1 on BBB permeability in vivo approximately 2 fold. Our results suggest that, besides its main function of recruiting leukocytes at sites of inflammation, MCP-1 also plays a role in 'opening' the BBB.
本研究旨在阐明趋化因子单核细胞趋化蛋白(MCP-1)对血脑屏障(BBB)通透性的影响。实验分别在体外条件下(脑内皮细胞与星形胶质细胞共培养)研究MCP-1的细胞效应,以及在体内条件下(脑内和脑室内注射MCP-1)研究MCP-1在体内对血脑屏障破坏的潜在作用。我们的结果表明,在体内条件下,MCP-1可使异硫氰酸荧光素(FITC)-白蛋白的血脑屏障通透表面积乘积显著增加,尤其是在长时间(3天或7天)暴露时(3天时,对照组为0.031±0.005 μL/g·min,MCP-1组为0.096±0.008 μL/g·min,P<0.001)。单核细胞趋化蛋白-1还增强了体外血脑屏障(共培养)模型的通透性(与对照组相比增加了17倍)。在细胞水平上,MCP-1导致内皮细胞紧密连接(TJ)蛋白发生改变(通过蛋白质印迹法确定TJ蛋白的重新分布,以及闭合蛋白、Claudin-5、ZO-1、ZO-2免疫染色的丧失)。单核细胞趋化蛋白-1诱导的血脑屏障通透性改变主要通过CCR2受体实现。缺乏CCR2可消除MCP-1在体外和体内对血脑屏障通透性的任何影响。在CCR2+/+和CCR2-/-小鼠中,暴露于MCP-1 3天后,FITC-白蛋白的通透表面积乘积分别为0.096±0.006和0.032±0.007 μL/g·min(P<0.001)。单核细胞/巨噬细胞也参与了MCP-1在体内诱导的血脑屏障通透性改变。单核细胞/巨噬细胞耗竭(通过氯膦酸盐脂质体)使MCP-1在体内对血脑屏障通透性的影响降低了约2倍。我们的结果表明,除了在炎症部位募集白细胞的主要功能外,MCP-1在“打开”血脑屏障方面也发挥作用。